- Home
- CPS vs ATXS Comparison
CPS vs ATXS Comparison
Compare CPS & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPS
- ATXS
- Stock Information
- Founded
- CPS 1960
- ATXS 2008
- Country
- CPS United States
- ATXS United States
- Employees
- CPS N/A
- ATXS N/A
- Industry
- CPS Auto Parts:O.E.M.
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- CPS Consumer Discretionary
- ATXS Health Care
- Exchange
- CPS Nasdaq
- ATXS Nasdaq
- Market Cap
- CPS 462.2M
- ATXS 401.2M
- IPO Year
- CPS N/A
- ATXS 2015
- Fundamental
- Price
- CPS $34.26
- ATXS $6.79
- Analyst Decision
- CPS Hold
- ATXS Buy
- Analyst Count
- CPS 1
- ATXS 6
- Target Price
- CPS $12.00
- ATXS $32.00
- AVG Volume (30 Days)
- CPS 249.8K
- ATXS 261.5K
- Earning Date
- CPS 07-31-2025
- ATXS 08-12-2025
- Dividend Yield
- CPS N/A
- ATXS N/A
- EPS Growth
- CPS N/A
- ATXS N/A
- EPS
- CPS 1.65
- ATXS N/A
- Revenue
- CPS $2,719,148,000.00
- ATXS N/A
- Revenue This Year
- CPS N/A
- ATXS N/A
- Revenue Next Year
- CPS $3.60
- ATXS N/A
- P/E Ratio
- CPS $20.85
- ATXS N/A
- Revenue Growth
- CPS N/A
- ATXS N/A
- 52 Week Low
- CPS $10.38
- ATXS $3.56
- 52 Week High
- CPS $35.11
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- CPS 81.20
- ATXS 55.19
- Support Level
- CPS $28.28
- ATXS $6.12
- Resistance Level
- CPS $29.50
- ATXS $7.14
- Average True Range (ATR)
- CPS 1.54
- ATXS 0.44
- MACD
- CPS 0.71
- ATXS -0.06
- Stochastic Oscillator
- CPS 92.60
- ATXS 63.76
About CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.